Table 3.
T lymphocytes
| T lymphocytes | Median count (first quartile, third quartile) |
Statistical analysis (p-value) | |||||
|---|---|---|---|---|---|---|---|
| DUP− | DUP+ | Control | KW test p value |
DUP+ versus DUP– | DUP– versus control | DUP+ versus control | |
| Relative T lymphocytes, % | 75.5 | 72.0 | 71.0 | 0.332 | |||
| (68.5, 79.5) | (62.5, 80.0) | (65.75, 77) | |||||
| Absolute T lymphocytes 109/l | 1.30 | 1.41 | 1.21 | 0.944 | |||
| (0.82, 1.56) | (0.83, 1.73) | (1.03, 1.63) | |||||
| Relative natural killers (NK), % | 9.0 | 9.0 | 9.5 | 0.925 | |||
| (6.25, 13) | (6.5, 14) | (5.75, 14) | |||||
| Absolute NK 109/l | 0.18 | 0.2 | 0.17 | 0.983 | |||
| (0.06, 0.28) | (0.09, 0.28) | (0.07, 0.29) | |||||
| Relative CD4 T lymphocytes, % | 65.0 | 74.0 | 62.5 | 0.002 | < 0.05 | < 0.01 | |
| (56.25, 73.0) | (68.5–80.0) | (54.0, 68.0) | |||||
| Absolute CD4 T lymphocytes 109/l | 1.1 | 1.32 | 1.07 | 0.406 | |||
| (0.66, 1.45) | (0.95, 1.91) | (0.86, 1.38) | |||||
| Relative CD8 T lymphocytes, % | 29.0 | 22.0 | 31.0 | 0.001 | < 0.001 | ||
| (21.25, 36.0) | (17.5, 25.0) | (26.5, 38.25) | |||||
| Absolute CD8 T lymphocytes 109/l | 0.48 | 0.36 | 0.59 | 0.045 | < 0.05 | < 0.05 | |
| (0.26, 0.65) | (0.28, 0.56) | (0.43, 0.73) | |||||
| Relative T regulatory, % | 1.0 | 1.0 | 0.8 | 0.225 | |||
| (0.7, 1.25) | (6.8, 1.6) | (0.7, 1.2) | |||||
| Absolute T regulatory 109/l | 0.01 | 0.02 | 0.015 | 0.637 | |||
| (0.01, 0.03) | (0.01, 0.03) | (0.01, 0.02) | |||||
DUP− patients without dupilumab treatment, DUP+ patients with dupilumab treatment, KW test results of Kruskal–Wallis test, NK natural killer cells. We show the significant difference in statistical analysis, p-value < 0.05
% is stated from all leukocytes
% of relative T regulatory lymphocytes is stated from CD4 T lymphocytes
% of CD8 and CD4 T lymphocytes is stated from all T lymphocytes